TNGX · NASDAQ
Tango Therapeutics, Inc.
$22.42 -0.92 (-3.94%)
Company overview
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers, and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $3.8B
- Employees
- 155
- Headquarters
- Boston, MA
- Website
- tangotx.com
- CEO
- Malte Peters
- Listed
- September 3, 2020
- P/E
- -27.06
- Dividend yield
- 0.00%
Company financials
- Revenue
- $57M
- Gross profit
- $55.4M
- Operating income
- -$118M
- EBITDA
- -$113M
- Net income
- -$107M
- EPS
- -$0.83
- Total assets
- $436M
- Total debt
- $32.8M
- Gross margin
- 97.25%
- Net margin
- -188.15%
- Earnings yield
- -3.70%
No geographic segmentation.
Showing FY 2025
TNGX
1D
NASDAQ
O25.54H25.94L22.68C23.34-4.59 (-16.43%)Vol15.85M